October/November #191 : Reduced Dose of Sustiva Succeeds - by Benjamin Ryan

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents
 

Features

¡El SIDA Sí Da!

Cut to Fit

From the Editor

Rie y Llora

Feedback

Letters-October/November 2013

The POZ Q+A

Unidos Podemos

POZ Planet

Thank You, Sean Sasser

On the March

Get Lucky

Friend Request

Then There Were None

Why Should Gay and Bi Latino Men Get Tested?

Say What? Zombie Edition

Voices

Obamacare is Here

Care and Treatment

Reduced Dose of Sustiva Succeeds

New Ways to Beat Gonorrhea

Lower Bone Density Linked to Number of ARV Regimens

No Detectable HIV in Two Men After Stem Cell Transplants

WHO Revises Treatment Guidelines

Research Notes

Prevention: HIV Test May Help Improve Vaccines

Treatment: Normal Mortality Risk if Undetectable?

Cure: Cord Blood Transplant Aftermath

Concerns: Early Treatment in Developing World

POZ Heroes

A Test of Kindness

   
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


email print

October / November 2013

Reduced Dose of Sustiva Succeeds

by Benjamin Ryan

Sustiva (efavirenz) is both safe and no less effective at fighting HIV when the standard dose is reduced by a third. Researchers conducted a global study of 630 HIV-positive participants who started their first antiretroviral regimen with either 600 or 400 milligrams of Sustiva plus Truvada (tenofovir and emtricitabine), which are the components of Atripla.  

After 48 weeks of treatment, 94 percent of those on the cut dose and 92 percent of those on the standard dose achieved a suppressed viral load—essentially equivalent results.

While reducing the Sustiva dose didn’t affect the number of adverse side effects or improve the drug’s tolerability, fewer people stopped treatment because of central nervous system reactions in the lower-dose group.

According to the study’s lead author, Rebekah Puls, PhD, of the University of New South Wales in Australia, the dose reduction translates to a savings of $20 per year per person in poorer nations.

Considering a new global push to greatly increase HIV treatment worldwide, Puls reflects, “That’s a huge savings. That’s literally millions and millions of dollars.”

Search: Sustiva, efavirenz, reduced dose, suppressed viral load, Rebekah Puls, PhD, University of New South Wales

Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Hide comments

Previous Comments:


         

[Go to top]

Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV 101
HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
Disclosing Your Status
Starting Treatment
Search for the Cure
POZ Stories
POZ TV
Read the Blogs
Visit the Forums
Women
African American
Latino
Providers
Job Listings
Events Calendar


    dhsd777
    san diego
    California


    Sloan1
    Dallas
    Texas


    cortaza100
    Chicago
    Illinois


    josebos
    KISSIMMEE
    Florida
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Can social media help stop HIV stigma?
Yes
No

Survey
Mind Matters

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.